Staar Surgical
This article was originally published in The Gray Sheet
Executive Summary
Phase III clinical trials for its intraocular Implantable Contact Lens for the treatment of myopia will begin following FDA go ahead. Staar, which so far has tested the ICL in 80 eyes, may now implant another 278 IOLs, while increasing the number of sites to 15, the company says. The Monrovia, California-based firm also may expand its study to treat patients with as little as -3 diopters of refractive error and reduce the waiting period for patients to receive an IOL in the second eye to 45 days from six months